If J&J’s going to keep rewarding investors, it’s going to need these top drugs to continue racking up sales.
Johnson & Johnson (NYSE:JNJ) recently shared its third-quarter financial report card with investors, and by all measures, it deserves kudos. However, the stock market rewards investors based on future expectations, not past successes. If J&J is going to keep putting up impressive results, it’s going to need to keep cashing in on its fastest-growing medicines.
Keys to growth
Johnson & Johnson markets top consumer-goods brands like Band-Aid, and it’s a big player in medical devices. But make no mistake -- this company’s success or failure depends heavily on the performance of its pharmaceuticals business.
